现金流、应收账款双重承压，博纳西亚冲刺港股IPO

Core Viewpoint - Bona Asia (Hangzhou) Pharmaceutical Technology Co., Ltd. has officially submitted its listing application to the Hong Kong Stock Exchange, with the aim of accelerating the development and commercialization of innovative drugs through digital empowerment in clinical research [1][3]. Company Overview - Bona Asia is a clinical contract research organization (CRO) based in Hangzhou, China, providing clinical trial technical services for pharmaceutical and biotechnology companies [3]. - The company was recently restructured into a joint-stock company and renamed on January 22, 2026 [3]. - The founder and chairman, Zhao Min, holds a controlling stake of approximately 78.33% in the company [3]. Financial Performance - In 2024, Bona Asia achieved a gross profit margin of 38.3%, significantly higher than the industry average of around 30% [4]. - The net profit margin for the same year was 19.8%, compared to the industry average of about 10% [4]. - The company reported revenues of approximately RMB 371 million in 2023, RMB 340 million in 2024, and RMB 245 million for the first three quarters of 2025 [4][5]. Revenue Breakdown - The clinical trial services for oncology and autoimmune diseases accounted for 51.1% of total revenue in 2023, increasing to 85.1% by the first three quarters of 2025 [4]. - The company has assisted in obtaining NDA approvals for 12 innovative drugs or therapies in China [4]. Cash Flow and Financial Health - The operating cash flow has turned negative in the first nine months of 2025, with a net cash outflow of RMB 353.5 million [7]. - Cash and cash equivalents decreased by 50.3% from RMB 1.11 billion at the end of 2024 to RMB 551.6 million by September 2025 [7]. - Trade receivables have been increasing, with RMB 90.04 million reported for the first nine months of 2025, leading to a deterioration in turnover days from 44 days in 2023 to 89 days by September 2025 [8][9]. Related Party Transactions - The company has significant receivables from related parties, amounting to RMB 89.67 million as of September 30, 2025, which poses a risk to cash flow [10][11]. - The company has indicated that these amounts may not be recoverable in full, impacting operational liquidity [12].